Boston Scientific, Inc. BSX recently received FDA approval for an expanded indication of the WaveWriter Alpha Spinal Cord Stimulator (“SCS”) Systems. With this approval, the system will be available ...
GlobalData on MSN
Boston Scientific touts long-term data of SCS therapy
At the recently concluded North American Neuromodulation Society annual meeting, Boston presented a total of 17 abstracts.
Just as a rising tide is said to lift all boats, so too is a new FDA clearance expanding the reach of all of Boston Scientific’s WaveWriter spinal cord stimulation systems. The devices—which include ...
Boston Scientific is hopping on the bandwagon as the latest developer of a spinal cord stimulation system to receive FDA approval for diabetic neuropathy pain relief. The newly handed-down regulatory ...
Marlborough medical technology firm Boston Scientific has received approval from the U.S. Food and Drug Administration for its WaveWriter Alpha spinal cord stimulator device to be used to treat low ...
System offers multiple non-drug therapies for people with chronic pain PARIS, Jan. 31, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Spectra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results